Trials / Completed
CompletedNCT02093611
Study to Examine the Effects of ATP Supplementation on Muscle Excitability and Reaction Time During and Following a Repeated Sprint Bout
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- Metabolic Technologies Inc. · Industry
- Sex
- Male
- Age
- 18 Years – 30 Years
- Healthy volunteers
- Accepted
Summary
We hypothesize that adenosine-5'-triphosphate (ATP) supplementation will be able to enhance motor unit recruitment while simultaneously blunting the decline in power and reaction time that is typically seen during repetitive sprints. This will give researchers a better understanding of the mechanism by which ATP supplementation can augment power, especially under high fatiguing conditions.
Detailed description
Healthy participants of similar training status as previously tested will be enrolled into the study. The participants will be randomly assigned to either placebo supplementation or to 400 mg ATP per day for 14 days. The supplements will be taken in the morning and the last dose will be taken 30 min prior to testing on the last day. Testing will be performed at baseline and after the 14 days of supplementation. Ten successive sprints will be conducted on the Wingate apparatus as this has been previously demonstrated to decrease muscle excitability. After the sprints, muscle excitability, reaction time, and vertical jump power will be measured. In addition a blood sample will be obtained before and after supplementation and complete blood hematology and chemistry analyses will be performed. It is expected that ATP supplementation may help maintain muscle excitability and power after the successive sprint sessions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Placebo | |
| DIETARY_SUPPLEMENT | ATP | 400 mg of ATP |
Timeline
- Start date
- 2013-07-01
- Primary completion
- 2015-08-01
- Completion
- 2015-08-01
- First posted
- 2014-03-21
- Last updated
- 2015-09-28
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02093611. Inclusion in this directory is not an endorsement.